相关临床试验
109
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1899
进行中（未招募）
6
5.5%
已完成
62
56.9%
Enrolling By Invitation
4
3.7%
尚未招募
2
1.8%
招募中
9
8.3%
暂停
2
1.8%
终止
5
4.6%
Unknown
17
15.6%
撤回
2
1.8%
暂无批准数据
- The Foundation for Sarcoidosis Research (FSR) announced 13 inaugural clinical sites for its national FSR Clinical Data Registry, including Brigham and Women's Hospital, Stanford, Yale, and Duke University. - The longitudinal, multi-center registry aims to improve understanding of sarcoidosis through standardized data collection across geographically and ethnically diverse patient populations. - FSR spent two years developing the protocol with input from patients, caregivers, clinicians, and pharmaceutical partners to address the disease's multi-disciplinary nature. - The registry will complement the existing FSR-SARC Patient Registry, creating a comprehensive resource to advance diagnosis, biomarker discovery, therapy assessment, and patient outcomes.
- Biodesix published the largest lung nodule biomarker clinical validation study ever conducted, analyzing over 1,100 patients with noncalcified lung nodules ranging from 4-30 mm in size. - The Nodify CDT® test demonstrated consistently high specificity of 91-97% across different nodule sizes and patient populations, indicating low false positive rates for lung cancer detection. - The validation study included data from four distinct clinical studies across 48 clinical practices in the US, including real-world clinical care settings. - Over 40% of malignant pulmonary nodules progress in tumor size between first detection and definitive treatment, highlighting the clinical need for improved decision-support tools.
- Paratek's omadacycline demonstrated significant bacterial burden reduction in a Phase II trial for nontuberculous mycobacterial pulmonary disease caused by Mycobacterium abscessus complex. - The study showed 76.5% of omadacycline-treated patients experienced decreased culture scores compared to 45.8% of placebo patients, with 53.8% achieving negative cultures at day 84. - Omadacycline addresses a critical unmet need in NTM treatment, where nearly all current therapies are used off-label, and has received FDA fast-track and orphan drug designations.
- Clarametyx Biosciences announced positive interim results from its Phase 1b/2a trial of CMTX-101, an immune-enabling antibody therapy for cystic fibrosis-associated pulmonary infections. - The interim analysis of 21 participants demonstrated a reduction in Pseudomonas aeruginosa burden with both 5 and 30 mg/kg doses, while maintaining a favorable safety profile. - The Independent Data Monitoring Committee approved continuation of the trial without modifications, with full enrollment of approximately 41 participants expected by end of 2025. - CMTX-101 targets bacterial biofilms to enhance antibiotic effectiveness and immune response, representing a novel approach to treating chronic respiratory infections.
- Phase 4 PASSAGE study demonstrates tezepelumab reduced annualized asthma exacerbation rates by 79% in real-world patients with severe asthma after 6 months of treatment. - The study included diverse patient populations often excluded from clinical trials, including those with COPD and smoking history, with significant benefits observed regardless of perennial allergy status. - Emergency department visits and hospitalizations decreased dramatically, with up to 95% reduction in patients with clinically relevant perennial allergies and 77% in those without.
